# Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours

> **NCT02303028** · PHASE1,PHASE2 · COMPLETED · sponsor: **The Hospital for Sick Children** · enrollment: 30 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Topotecan and Pazopanib

## Key facts

- **NCT ID:** NCT02303028
- **Lead sponsor:** The Hospital for Sick Children
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2022-06-17
- **Final completion:** 2022-06-17
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02303028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02303028, "Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02303028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*